Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Disease Progression × Fulvestrant × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 322 Neoplasm Metastasis 39 Neoplasms 25 Ovarian Neoplasms 19 Advanced Breast Cancer 18 Carcinoma, Non-Small-Cell Lung 13 Endometrial Neoplasms 11 Prostatic Neoplasms 10 Hereditary Sensory and Autonomic Neuropathies 8 Triple Negative Breast Neoplasms 7 Breast Cancer Metastatic 6 Uterine Cervical Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Recurrence 5 Multiple Endocrine Neoplasia Type 1 5 Colorectal Neoplasms 5 Carcinoma, Ovarian Epithelial 5 Breast Diseases 5 Neoplasms by Site 4 Stomach Neoplasms 3 Small Cell Lung Carcinoma 3 Pancreatic Neoplasms 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Fallopian Tube Neoplasms 3 Carcinoma, Lobular 3 Breast Neoplasm Female 3 Uterine Neoplasms 2 Melanoma 2 Lymphoma, Non-Hodgkin 2

Interventions

Lenalidomide 4 Gemcitabine 4 Dexamethasone 4 Cyclophosphamide 4 Bortezomib 4 Nivolumab 3 Cisplatin 3 Carboplatin 3 vandetanib 2 tumor necrosis factor-alpha, CNGRC fusion protein, human 2 pomalidomide 2 pembrolizumab 2 liposomal doxorubicin 2 fludarabine 2 durvalumab 2 capivasertib 2 Radiosurgery 2 Paclitaxel 2 Doxorubicin 2 Bevacizumab 2 Anthropogenic Effects 2 venetoclax 1 umbralisib 1 ublituximab 1 tremelimumab 1 tivozanib 1 ricolinostat 1 regorafenib 1 pazopanib 1 niraparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06635447 2026-03-27

CAPItrue

AstraZeneca

Phase 3 Active not recruiting

Breast Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡